8月6日,福建海西新药创制股份有限公司(简称“海西新药”)再次向港交所递交招股书,华泰国际和招银国际担任其联席保荐人。今年1月3日,海西新药首次递交招股书。 与多家创新药企业在亏损状态下遵从18A制度谋求在港股上市的情况不同,海西新药拥有获得国家药监局批准的14款仿制药,并凭借仿制药的销售实现盈利。2024年,海西新药来自VBP(即国家药品集中带量采购)计划的销售金额占总销售金额的九成。 但其...
Source Link8月6日,福建海西新药创制股份有限公司(简称“海西新药”)再次向港交所递交招股书,华泰国际和招银国际担任其联席保荐人。今年1月3日,海西新药首次递交招股书。 与多家创新药企业在亏损状态下遵从18A制度谋求在港股上市的情况不同,海西新药拥有获得国家药监局批准的14款仿制药,并凭借仿制药的销售实现盈利。2024年,海西新药来自VBP(即国家药品集中带量采购)计划的销售金额占总销售金额的九成。 但其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.